Last SFr.26.05 CHF
Change Today 0.00 / 0.00%
Volume 0.0
PFE On Other Exchanges
Symbol
Exchange
New York
Xetra
Mexico
SIX Swiss Ex
Stockholm
London
Sao Paulo
Bogota
As of 11:43 AM 08/19/14 All times are local (Market data is delayed by at least 15 minutes).

pfizer inc (PFE) Snapshot

Open
SFr.26.05
Previous Close
SFr.26.05
Day High
--
Day Low
--
52 Week High
11/14/13 - SFr.29.50
52 Week Low
08/8/14 - SFr.25.40
Market Cap
165.2B
Average Volume 10 Days
745.1
EPS TTM
--
Shares Outstanding
6.3B
EX-Date
07/30/14
P/E TM
--
Dividend
SFr.1.04
Dividend Yield
3.50%
Current Stock Chart for PFIZER INC (PFE)

pfizer inc (PFE) Details

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines, and various consumer healthcare products. The company’s Primary Care segment offers prescription pharmaceutical products primarily prescribed by primary-care physicians for various therapeutic and disease areas comprising Alzheimer’s disease, cardiovascular, erectile dysfunction, genitourinary, major depressive disorder, pain, respiratory, and smoking cessation. Its Specialty Care and Oncology segment provides prescription pharmaceutical products for anti-infectives, endocrine disorders, hemophilia, inflammation, ophthalmology, pulmonary arterial hypertension, specialty neuroscience, and vaccines, as well as oncology and oncology-related illnesses. The company’s Established Products and Emerging Markets segment offers prescription pharmaceutical products that had lost patent protection or marketing exclusivity in certain countries and/or regions, as well as sold in emerging markets, including Asia, Latin America, the Middle East, Eastern Europe, Africa, Turkey, and Central Europe. Its Consumer Healthcare segment provides non-prescription products in a range of therapeutic categories, such as dietary supplements, pain management, respiratory, and personal care. The company also offers Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Norvasc, Sutent, and the Premarin family of products; and consumer healthcare products under the Advil, Caltrate, Centrum, ChapStick, Emergen-C, Preparation H, and Robitussin brands. It serves wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, and grocery and convenience stores. It has strategic alliance with CliniWorks (Israel) Ltd. to develop population health management platform with advanced analytics and patient care capabilities. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

77,700 Employees
Last Reported Date: 02/28/14
Founded in 1849

pfizer inc (PFE) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.8M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $1.2M
President of Worldwide Research and Developme...
Total Annual Compensation: $1.1M
Group President of Global Innovative Pharma B...
Total Annual Compensation: $926.3K
Group President of Global Established Pharma ...
Total Annual Compensation: $810.1K
Compensation as of Fiscal Year 2013.

pfizer inc (PFE) Key Developments

Pfizer Announces Submission of Palbociclib New Drug Application to the FDA

Pfizer Inc. announced it has completed the submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for palbociclib. This NDA requests FDA approval of palbociclib, in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer who have not received previous systemic treatment for their advanced disease. The submission is based on the final results of PALOMA-1, a randomized, Phase 2 trial comparing palbociclib plus letrozole versus letrozole alone in this population of patients. Palbociclib received Breakthrough Therapy designation from the FDA in April 2013, for the first-line systemic treatment of women with advanced or metastatic ER+, HER2- breast cancer. This designation was based on interim data from the PALOMA-1 trial. The FDA has a 60-day filing review period to determine whether the NDA is complete and acceptable for filing. Pfizer will communicate the Agency's decision.

Pfizer Announces FDA Acceptance Of And Priority Review Designation For Biologics License Application For Investigational Meningococcal B Vaccine

Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bivalent recombinant LP2086 (rLP2086), the company's vaccine candidate for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 through 25 year olds. The FDA has also granted Priority Review designation for the BLA, providing an anticipated Prescription Drug User Fee Act (PDUFA) action date of February 14, 2015.

Pfizer Inc. Receives Recommendation for Prevnar 13(R) (Pneumococcal 13-Valent Conjugate Vaccine [Diphtheria CRM(197) Protein])PCV13) for Routine Use

Pfizer Inc. announced that the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend Prevnar 13(R) (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM(197) Protein])PCV13) for routine use to help protect adults aged 65 years and older against pneumococcal disease, which includes pneumonia caused by the 13 pneumococcal serotypes included in the vaccine. Specifically, the ACIP voted to recommend the adults 65 years of age or older who have not previously received pneumococcal vaccine or whose previous vaccination history is unknown should receive a dose of PCV13 first, followed by a dose of PPSV23. Adults 65 years of age or older who have not previously received PCV13 and who have previously received one or more doses of PPSV23 should receive a dose of PCV13. The recommendations for routine PCV13 use among adults 65 years and older* should be re-evaluated in 2018 and revised as needed. The recommendations, including the time intervals between vaccines, will be forwarded to the director of the CDC and the U.S. Department of Health and Human Services for review and approval; once approved, the recommendations are published in the Morbidity and Mortality Weekly Report. Pneumococcal pneumonia is the most common type of community-acquired bacterial pneumonia in the United States. About 900,000 Americans get pneumococcal pneumonia each year, nearly half of whom end up in the hospital. Among adults 50 years of age and older, there are approximately 440,000 cases of pneumococcal pneumonia each year in the United States, with approximately 25,000 pneumococcal disease-related deaths annually.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PFE:SW SFr.26.05 CHF 0.00

PFE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bayer AG €98.91 EUR -0.48
Gilead Sciences Inc $101.28 USD +0.56
Merck & Co Inc $58.91 USD +0.49
Roche Holding AG SFr.266.60 CHF +1.20
Procter & Gamble Co/The $82.69 USD +0.25
View Industry Companies
 

Industry Analysis

PFE

Industry Average

Valuation PFE Industry Range
Price/Earnings 18.2x
Price/Sales 3.6x
Price/Book 2.4x
Price/Cash Flow 12.4x
TEV/Sales 2.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PFIZER INC, please visit www.pfizer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.